Pitavastatin reduces inflammation in atherosclerotic plaques in apolipoprotein E-deficient mice with late stage renal disease

PLoS ONE

Volumn 10, Issue 9, 2015, Pages

  Shibasaki, Manabu ^a   Wang, Jian Guo ^a   Figueiredo, Jose Luiz ^a   New, Sophie E P ^a   Quillard, Thibaut ^a   Goettsch, Claudia ^a   Koga, Jun Ichiro ^a   Sonoki, Hiroyuki ^a   Matsumoto, Jiro ^a   Aikawa, Masanori ^a   Aikawa, Elena ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CHOLESTEROL; OSTEOPONTIN; PHOSPHATE; PITAVASTATIN; APOLIPOPROTEIN E; QUINOLINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERITIS; ARTERY CALCIFICATION; ARTERY OCCLUSION; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BRACHIOCEPHALIC TRUNK; CHOLESTEROL DIET; CONTROLLED STUDY; DRUG EFFECT; ECHOGRAPHY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INFLAMMATION; KIDNEY DISEASE; MACROPHAGE; MALE; MOLECULAR IMAGING; MOUSE; MOUSE STRAIN; NEPHRECTOMY; NONHUMAN; PERITONEUM MACROPHAGE; PHOSPHATE BLOOD LEVEL; PROTEIN EXPRESSION; ANIMAL; BLOOD; DEFICIENCY; DIAGNOSTIC IMAGING; GENETICS; HUMAN; KIDNEY FAILURE, CHRONIC; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; PLAQUE, ATHEROSCLEROTIC;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CALCIUM; CHOLESTEROL; HUMANS; KIDNEY FAILURE, CHRONIC; MACROPHAGES, PERITONEAL; MICE; MICE, KNOCKOUT; OSTEOPONTIN; PHOSPHATES; PLAQUE, ATHEROSCLEROTIC; QUINOLINES; ULTRASONOGRAPHY;

EID: 84947548546     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0138047     Document Type: Article

References (50)

1. Otto CM (2008) Calcific aortic stenosis-time to look more closely at the valve. N Engl J Med 359:1395-1398. doi: 10.1161/CIRCULATIONAHA.110.006767 PMID: 22007101
2. Johnson RC, Leopold JA, Loscalzo J (2006) Vascular calcification: pathobiological mechanisms and clinical implications. Circ Res 99:1044-1059. PMID: 17095733
3. Demer LL, Tintut Y (2008) Vascular calcification: pathobiology of a multifaceted disease. Circulation 117:2938-2948. doi: 10.1161/CIRCULATIONAHA.107.743161 PMID: 18519861
4. Towler DA (2008) Vascular calcification: a perspective on an imminent disease epidemic. IBMS Bone-KEy 5:41-58.
5. Kalaitzidis RG, Elisaf MS (2011) The role of statins in chronic kidney disease. Am J Nephrol 34:195-202. doi: 10.1159/000330355 PMID: 21791915
6. Levin A (2011) Nondialysis chronic kidney disease in 2011: Progression, prediction, populations and possibilities. Nat Rev Nephrol 8:70-72. doi: 10.1038/nrneph.2011.195 PMID: 22143330
7. Moody WE, Edwards NC, Madhani M, Chue CD, Steeds RP, Ferro CJ, et al. (2012) Endothelial dysfunction and cardiovascular disease in early-stage chronic kidney disease: cause or association? Atherosclerosis 223:86-94. doi: 10.1016/j.atherosclerosis.2012.01.043 PMID: 22349087
8. Swaminathan S, Shah SV (2011) Novel inflammatory mechanisms of accelerated atherosclerosis in kidney disease. Kidney Int 80:453-463. doi: 10.1038/ki.2011.178 PMID: 21697810
9. Aikawa E, Aikawa M, Libby P, Figueiredo JL, Rusanescu G, Iwamoto Y, et al. (2009) Arterial and aortic valve calcification abolished by elastolytic cathepsin S deficiency in chronic renal disease. Circulation 119:1785-1794. doi: 10.1161/CIRCULATIONAHA.108.827972 PMID: 19307473
10. Kon V, Linton MF, Fazio S (2011) Atherosclerosis in chronic kidney disease: the role of macrophages. Nat Rev Nephrol 7:45-54. doi: 10.1038/nrneph.2010.157 PMID: 21102540
11. Massy ZA, Ivanovski O, Nguyen-Khoa T, Angulo J, Szumilak D, Mothu N, et al. (2005) Uremia accelerates both atherosclerosis and arterial calcification in apolipoprotein E knockout mice. J Am Soc Nephrol 16:109-116. PMID: 15563564
12. Schwarz U, Buxello M, Ritz E, Stein G, Raabe G, Wiest G, et al. (2000) Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant 15:218-223. PMID: 10648668
13. Saito Y (2009) Critical appraisal of the role of pitavastatin in treating dyslipidemias and achieving lipid goals. Vasc Health Risk Manag 5:921-936. PMID: 19997573
14. Zheng C, Azcutia V, Aikawa E, Figueiredo JL, Croce K, Sonoki H, et al. (2013) Statins suppress apolipoprotein CIII-induced vascular endothelial cell activation and monocyte adhesion. Eur Heart J 34:615-624. doi: 10.1093/eurheartj/ehs271 PMID: 22927557
15. Libby P, Aikawa M (2003) Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. Nat Med 8:1257-1262. PMID: 12411953
16. Robinson JG, Smith B, Maheshwari N, Schrott H (2005) Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll Cardiol 46:1855-1862. PMID: 16286171
17. Laufs U, La Fata V, Plutzky J, Liao JK (1998) Upregulation of endothelial nitric oxide synthase by HMGCoA reductase inhibitors. Circulation 97:1129-1135. PMID: 9537338
18. Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ, et al. (2000) The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 6:1004-1010. PMID: 10973320
19. Aikawa M, Rabkin E, Sugiyama S, Voglic SJ, Fukumoto Y, Furukawa Y, et al. (2001) An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 103:276-283. PMID: 11208689
20. Fukumoto Y, Libby P, Rabkin E, Hill CC, Enomoto M, Hirouchi Y, et al. (2001) Statins alter smooth muscle cell accumulation and collagen content in established atheroma of Watanabe heritable hyperlipidemic rabbits. Circulation 103:993-999. PMID: 11181475
21. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, et al. (2001) Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. New Engl J Med 344:1959-1965. PMID: 11430324
22. Scalia R, Gooszen ME, Jones SP, Hoffmeyer M, Rimmer DM III, Trocha SD, et al. (2001) Simvastatin exerts both anti-inflammatory and cardioprotective effects in apolipoprotein E-deficient mice. Circulation 103:2598-2603. PMID: 11382730
23. Kimata H, Fujino H, Koide T, Yamada Y, Tsunenari Y, Yanagawa Y. (1998) Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (1): Absorption, distribution, metabolism and excretion in rats. Xenobio Metabol Dispo 13:484-498.
24. Aikawa E, Nahrendorf M, Figueiredo JL, Swirski FK, Shtatland T, Kohler RH, et al. (2007) Osteogenesis associates with inflammation in early-stage atherosclerosis evaluated by molecular imaging in vivo. Circulation 116:2841-2850. PMID: 18040026
25. Thukkani AK, Jaffer FA (2013) Intravascular near-infrared fluorescence molecular imaging of atherosclerosis. Am J Nucl Med Mol Imaging 3:217-231. PMID: 23638334
26. Matter CM, Stuber M, Nahrendorf M (2009) Imaging of the unstable plaque: how far have we got? Eur Heart J 30:2566-2574. doi: 10.1093/eurheartj/ehp419 PMID: 19833636
27. Koga J, Matoba T, Egashira K, Kubo M, Miyagawa M, Iwata E, et al. (2009) Soluble Flt-1 gene transfer ameliorates neointimal formation after wire injury in flt-1 tyrosine kinase-deficient mice. Arterioscler Thromb Vasc Biol 29:458-464. doi: 10.1161/ATVBAHA.109.183772 PMID: 19164801
28. Bot I, Jukema JW, Lankhuizen IM, van Berkel TJ, Biessen EA (2011) Atorvastatin inhibits plaque development and adventitial neovascularization in ApoE deficient mice independent of plasma cholesterol levels. Atherosclerosis 214:295-300. doi: 10.1016/j.atherosclerosis.2010.11.008 PMID: 21130458
29. Sparrow CP, Burton CA, Hernandez M, Mundt S, Hassing H, Patal S, et al. (2001) Simvastatin has antiinflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol 21:115-121. PMID: 11145942
30. Sata M, Nishimatsu H, Osuga J, Tanaka K, Ishizaka N, Ishibashi S, et al. (2004) Statins augment collateral growth in response to ischemia but they do not promote cancer and atherosclerosis. Hypertension 43:1214-1220. PMID: 15166180
31. Cho HJ, Cho HJ, Kim HS (2009) Osteopontin: a multifunctional protein at the crossroads of inflammation, atherosclerosis, and vascular calcification. Curr Atheroscler Rep 11:206-213. PMID: 19361352
32. Nakamachi T, Nomiyama T, Gizard F, Heywood EB, Jones KL, Zhao Y, et al. (2007) PPARalpha agonists suppress osteopontin expression in macrophages and decrease plasma levels in patients with type 2 diabetes. Diabetes 56:1662-1670. PMID: 17360982
33. Ogawa D, Stone JF, Takata Y, Blaschke F, Chu VH, Towler DA, et al. (2005) Liver x receptor agonists inhibit cytokine-induced osteopontin expression in macrophages through interference with activator protein-1 signaling pathways. Circ Res 96:e59-e67. PMID: 15790955
34. Zhao W, Wang L, Zhang M, Wang P, Zhang L, Yuan C, et al. (2011) NF-κB- and AP-1-mediated DNA looping regulates osteopontin transcription in endotoxin-stimulated murine macrophages. J Immunol 186:3173-3179. doi: 10.4049/jimmunol.1003626 PMID: 21257959
35. Beck GR Jr., Knecht N (2003) Osteopontin regulation by inorganic phosphate is ERK1/2-, protein kinase C-, and proteasome-dependent. J Biol Chem 278:41921-41929. PMID: 12920127
36. Takemoto M, Kitahara M, Yokote K, Asaumi S, Take A, Saito Y, et al. (2001) NK-104, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, reduces osteopontin expression by rat aortic smooth muscle cells. Br J Pharmacol 133:83-88. PMID: 11325797
37. Kadoglou NP, Kottas G, Lampropoulos S, Vitta I, Liapis CD (2014) Serum levels of fetuin-A, osteoprotegerin and osteopontin in patients with coronary artery disease: effects of statin (HMGCoA-reductase inhibitor) therapy. Clin Drug Investig 34:165-171. doi: 10.1007/s40261-013-0157-y PMID: 24307429
38. Fatherazi S, Matsa-Dunn D, Foster BL, Rutherford RB, Somerman MJ, Presland RB. (2009) Phosphate regulates osteopontin gene transcription. J Dent Res 88:39-44. doi: 10.1177/0022034508328072 PMID: 19131315
39. Hirota S, Imakita M, Kohri K, Ito A, Morii E, Adachi S, et al. (1993) Expression of osteopontin messenger RNA by macrophages in atherosclerotic plaques. A possible association with calcification. Am J Pathol 143:1003-1008. PMID: 8213995
40. Liaw L, Lombardi DM, Almeida MM, Schwartz SM, deBlois D, Giachelli CM. (1997) Neutralizing antibodies directed against osteopontin inhibit rat carotid neointimal thickening after endothelial denudation. Arterioscler Thromb Vasc Biol 17:188-193. PMID: 9012655
41. Matsui Y, Rittling SR, Okamoto H, Inobe M, Jia N, Shimizu T, et al. (2003) Osteopontin deficiency attenuates atherosclerosis in female apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 23:1029-1034. PMID: 12730087
42. Shao JS, Sierra OL, Cohen R, Mecham RP, Kovacs A, Wang J, et al. (2011) Vascular calcification and aortic fibrosis: a bifunctional role for osteopontin in diabetic arteriosclerosis. Arterioscler Thromb Vasc Biol 31:1821-1833. doi: 10.1161/ATVBAHA.111.230011 PMID: 21597007
43. Ashkar S, Weber GF, Panoutsakopoulou V, Sanchirico ME, Jansson M, Zawaideh S, et al. (2000) Eta-1 (Osteopontin): An early component of type-1 (cell-mediated) immunity. Science 287:860-864. PMID: 10657301
44. Mazhar AR, Johnson RJ, Gillen D, Stivelman JC, Ryan MJ, Davis CL, et al. (2001) Risk factors and mortality associated with calciphylaxis in end-stage renal disease. Kidney Int 60:324-332. PMID: 11422768
45. El-Abbadi MM, Pai AS, Leaf EM, Yang HY, Bartley BA, Quan KK, et al. (2009) Phosphate feeding induces arterial medial calcification in uremic mice: role of serum phosphorus, fibroblast growth factor-23, and osteopontin. Kidney Int 75:1297-1307. doi: 10.1038/ki.2009.83 PMID: 19322138
46. Ellam TJ, Chico TJ (2012) Phosphate: the new cholesterol? The role of the phosphate axis in non-uremic vascular disease. Atherosclerosis 220:310-318. doi: 10.1016/j.atherosclerosis.2011.09.002 PMID: 21962238
47. Ivanovski O, Szumilak D, Nguyen-Khoa T, Nikolov IG, Joki N, Mothu N, et al. (2008) Effect of simvastatin in apolipoprotein E deficient mice with surgically induced chronic renal failure. J Urol 179:1631-1636. doi: 10.1016/j.juro.2007.11.042 PMID: 18295249
48. Fujii M, Inoguchi T, Maeda Y, Sasaki S, Sawada F, Saito R, et al. (2007) Pitavastatin ameliorates albuminuria and renal mesangial expansion by downregulating NOX4 in db/db mice. Kidney Int 72:473-480. PMID: 17568784
49. Cheng XW, Kuzuya M, Sasaki T, Inoue A, Hu L, Song H, et al. (2011) Inhibition of mineralocorticoid receptor is a renoprotective effect of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor pitavastatin. J Hypertens 29:542-552. doi: 10.1097/HJH.0b013e328341cedf PMID: 21119529
50. Haynes R, Lewis D, Emberson J, Reith C, Agodoa L, Cass A, et al. (2014) Effects of lowering LDL cholesterol on progression of kidney disease. J Am Soc Nephrol 25:1825-1833. doi: 10.1681/ASN.2013090965 PMID: 24790178